Clear Search sequence regions
Bookmark Forward

Literature for Liver


Results presented below are derived from data collected from over 475 news feeds.

Filter your search Help

1 to 10 of 5,154 stories

  • Neonics are being ingested by free-ranging animals

    Science Daily. - June 20, 2018

    University of Guelph researchers found residues of the insecticides in the livers of wild turkeys, providing evidence that this common agrochemical is being ingested by free-ranging animals.

  • 's Daily Biotech Pulse: Galmed Rips Higher On Positive...

    Biotech News. - June 12, 2018

    Galmed Pharmaceuticals Ltd released Phase 2b data for Arabchol that is evaluated in a study called ARREST for treating non-alcoholic steatohepatitis, or NASH, which showed statistically significant reduction in liver fat, as demonstrated by Magnetic Resonance Spectroscopy in patients …

  • Israeli company Galmed gets positive trial results for liver drug

    Reuters. - June 12, 2018

    TEL AVIV (Reuters) - Galmed Pharmaceuticals said on Tuesday patients in a mid-stage trial for its treatment for NASH, a fatty liver disease linked to obesity, showed a statistically significant reduction in liver fat.

  • When push comes to shove: Airway cells propel liver cancer spread to lungs

    Science Daily. - June 01, 2018

    Researchers identified a crucial role for air sac-based scavenger blood cells, alveolar macrophages (AMs), in driving hepatocellular cancer metastasis in the lungs. AMs were found to be recruited by interstitial macrophages (IMs) through interactions between the IM-expressed signaling…

  • EMA issues measures to minimize liver damage risk from Richter's Esmya

    Reuters. - June 01, 2018

    (Reuters) - European Medicines Agency issued guidelines on Friday to help minimize the risk of rare but serious liver injury associated with Hungarian drugmaker Richter's Esmya.

  • Madrigal Pharma more than doubles after liver drug study success

    Reuters. - May 31, 2018

    (Reuters) - Madrigal Pharmaceuticals Inc's shares more than doubled after mid-stage trial data showed its lead drug reduced liver fat in patients with fatty liver disease, placing it ahead of larger rivals to tap into a potential market worth $30 billion.

  • Madrigal Pharma's liver drug succeeds in study, shares soar

    Reuters. - May 31, 2018

    (Reuters) - Madrigal Pharmaceuticals Inc's lead experimental drug achieved the main goal of reducing liver fat in patients with fatty liver disease in a mid-stage study, sending its shares surging 66 percent in premarket trading on Thursday.

  • Madrigal Pharma's liver disease drug succeeds in study, shares soar

    Reuters. - May 31, 2018

    (Reuters) - Madrigal Pharmaceuticals Inc said on Thursday its lead experimental drug achieved the main goal of reducing liver fat in patients with a type of liver disease in a mid-stage study, sending its shares surging 40 percent in premarket trading.

  • Madrigal Pharma's liver disease drug succeeds in mid-stage trial

    Reuters. - May 31, 2018

    (Reuters) - Madrigal Pharmaceuticals Inc said on Thursday a mid-stage trial testing its lead experimental treatment for a liver disease achieved the main goal of reducing liver fat.

  • 5 kinds of hepatitis all attack one organ in the body

    Biotech News. - May 29, 2018

    All five kinds of hepatitis - A, B, C, D and E - target the liver but do so in different ways with different outcomes, according to the federal Centers for Disease Control and Prevention. They're all called hepatitis is because the word itself, from the Greek hepar + itis, means liver…